Cargando…
Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story
Plants are a promising alternative for the production of biotherapeutics. Manufacturing in-planta adds plant specific glycans. To understand immunogenic potential of these glycans, we developed a validated method to detect plant specific glycan antibodies in human serum. Using this assay, low preval...
Autores principales: | Rup, Bonita, Alon, Sari, Amit-Cohen, Bat-Chen, Brill Almon, Einat, Chertkoff, Raul, Tekoah, Yoram, Rudd, Pauline M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663370/ https://www.ncbi.nlm.nih.gov/pubmed/29088235 http://dx.doi.org/10.1371/journal.pone.0186211 |
Ejemplares similares
-
Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease
por: Abbas, Richat, et al.
Publicado: (2015) -
Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016) -
Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2016) -
Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa
por: Zimran, Ari, et al.
Publicado: (2018) -
Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe?
por: Paskulin, Livia, et al.
Publicado: (2019)